{
    "2021-08-16": [
        [
            {
                "time": "",
                "original_text": "通策医疗：目前公司重点发展口腔医疗服务，辅助生殖业务贡献较小",
                "features": {
                    "keywords": [
                        "通策医疗",
                        "口腔医疗",
                        "辅助生殖"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "口腔医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "海通证券：维持通策医疗(600763.SH)“优于大市”评级 价值区间277.47-312.15元",
                "features": {
                    "keywords": [
                        "海通证券",
                        "通策医疗",
                        "评级",
                        "优于大市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "通策医疗(600763)：单Q2高基数下净利润比增13% 业绩增长稳健",
                "features": {
                    "keywords": [
                        "通策医疗",
                        "净利润",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：医疗服务三问三答 何时会出现板块性机会？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医疗服务",
                        "板块性机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "医疗服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：关注CXO新秀 重点推荐皓元医药、诺泰生物等",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CXO",
                        "皓元医药",
                        "诺泰生物"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "CXO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "西部证券维持通策医疗买入评级，2021半年报点评：业绩维持高增长，蒲公英计划快速推进",
                "features": {
                    "keywords": [
                        "西部证券",
                        "通策医疗",
                        "买入评级",
                        "蒲公英计划"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}